在研机构- |
权益机构- |
最高研发阶段终止临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评快速通道 (美国)、孤儿药 (美国) |
分子式C22H18FN5O2 |
InChIKeyJQBUTSBIFNKJMW-CYBMUJFWSA-N |
CAS号2490674-02-5 |
开始日期2026-03-30 |
申办/合作机构 |
开始日期2025-12-13 |
申办/合作机构 |
开始日期2021-12-13 |
申办/合作机构 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D12782 | - | - | - |
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 镰状细胞血症 | 临床2期 | 美国 | 2026-03-30 | |
| 半规管裂综合征 | 临床2期 | 美国 | 2026-03-30 | |
| 急性胸部综合征 | 临床1期 | 美国 | 2021-12-13 | |
| 急性胸部综合征 | 临床1期 | 尼日利亚 | 2021-12-13 | |
| 急性胸部综合征 | 临床1期 | 南非 | 2021-12-13 |
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床1期 | 29 | 願鑰網繭廠範觸廠膚糧(衊製齋選餘鏇鹽願餘願) = 範夢簾憲觸夢餘積蓋鹹 觸淵餘憲鬱淵獵憲齋構 (鹽蓋壓範獵鑰積遞襯簾 ) 更多 | 积极 | 2026-05-12 | |||
願鑰網繭廠範觸廠膚糧(衊製齋選餘鏇鹽願餘願) = 獵獵鬱糧淵獵範範鏇餘 觸淵餘憲鬱淵獵憲齋構 (鹽蓋壓範獵鑰積遞襯簾 ) 更多 | |||||||
临床1期 | 13 | 壓襯醖窪構窪蓋艱遞餘(蓋鬱範築獵憲獵鹹鏇鬱) = 簾願顧願遞選築積顧願 鹹衊積構蓋願顧簾選範 (構顧獵觸夢膚顧蓋餘鬱 ) 更多 | 积极 | 2026-02-24 | |||
临床1期 | 16 | 獵獵壓鬱餘網壓製繭網(窪構積鏇範齋構鑰鹹膚) = 鬱鑰選簾艱餘餘窪衊願 膚鏇鬱淵鏇餘築鹽齋鑰 (鬱遞淵鏇製範獵顧遞製 ) 更多 | 积极 | 2025-12-06 | |||
临床1期 | 16 | 夢願築鏇製簾繭獵鏇蓋(夢壓廠簾構獵齋鏇憲積) = 鬱繭獵顧獵壓糧夢艱壓 製繭壓艱鬱鏇膚鏇廠鏇 (鹹範觸壓繭構廠糧觸憲 ) 更多 | 积极 | 2025-07-29 | |||
临床1期 | 16 | POCIREDIR 2 mg | 夢鹽築艱簾衊選蓋網齋(範鏇醖糧衊廠選鹹遞壓) = 23 TEAEs in 10/16 adults (63%) with 8/23 possibly related to study drug (headache [x2], lipnumbness, diarrhea, tinnitus, fatigue, drowsiness, nausea); they were all mild in severity, non-serious, andresolved quickly; all patients remained on study drug. 4/23 TEAEs were VOCs; one was reported as an SAE withacute chest syndrome and was deemed unrelated to study drug, and occurred in a patient who was non-adherent to pociredir. The other three VOCs were non-serious, mild or moderate in severity, and were treatedin an outpatient setting. 廠選憲廠艱膚製遞積窪 (觸餘製齋廠鏇構廠鏇繭 ) 更多 | 积极 | 2024-05-14 | ||
POCIREDIR 6 mg | |||||||
EHA2022 人工标引 | 临床1期 | - | 鹹築築鬱簾餘膚獵襯構(夢衊糧築壓範鹹衊積蓋) = 鑰淵範餘顧遞選壓願繭 願淵獵窪網窪蓋膚獵積 (繭齋壓鑰範淵積構艱遞 ) 更多 | 积极 | 2022-05-12 | ||
临床1期 | - | 鹽遞壓遞膚範夢積齋糧(蓋願餘餘糧鑰夢鬱廠簾) = 構築鑰鑰製艱窪襯鏇襯 夢齋糧觸鬱膚構選遞鑰 (選遞範觸繭醖獵鹹窪製 ) 更多 | 积极 | 2021-08-10 |





